Joseph R. Young Sells 5,714 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA) Stock

Vera Therapeutics, Inc. (NASDAQ:VERA) SVP Joseph R. Young sold 5,714 shares of the stock in a transaction that occurred on Wednesday, April 10th. The stock was sold at an average price of $40.00, for a total transaction of $228,560.00. Following the transaction, the senior vice president now directly owns 53,171 shares of the company’s stock, valued at approximately $2,126,840. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Vera Therapeutics Price Performance

Shares of VERA opened at $47.97 on Friday. Vera Therapeutics, Inc. has a twelve month low of $6.05 and a twelve month high of $50.78. The firm’s fifty day simple moving average is $43.39 and its 200-day simple moving average is $25.05. The firm has a market capitalization of $2.61 billion, a price-to-earnings ratio of -20.95 and a beta of 1.05. The company has a current ratio of 7.71, a quick ratio of 7.71 and a debt-to-equity ratio of 0.49.

Institutional Investors Weigh In On Vera Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC raised its holdings in shares of Vera Therapeutics by 39.7% in the 1st quarter. FMR LLC now owns 5,796,259 shares of the company’s stock valued at $44,979,000 after purchasing an additional 1,647,613 shares in the last quarter. Kynam Capital Management LP raised its holdings in shares of Vera Therapeutics by 23.5% in the 4th quarter. Kynam Capital Management LP now owns 3,650,339 shares of the company’s stock valued at $56,142,000 after purchasing an additional 694,286 shares in the last quarter. BlackRock Inc. raised its holdings in shares of Vera Therapeutics by 53.9% in the 2nd quarter. BlackRock Inc. now owns 2,170,134 shares of the company’s stock valued at $34,831,000 after purchasing an additional 759,864 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Vera Therapeutics by 1.6% in the 2nd quarter. Citadel Advisors LLC now owns 2,122,851 shares of the company’s stock valued at $28,892,000 after purchasing an additional 33,331 shares in the last quarter. Finally, Vanguard Group Inc. raised its holdings in shares of Vera Therapeutics by 3.8% in the 4th quarter. Vanguard Group Inc. now owns 1,633,608 shares of the company’s stock valued at $25,125,000 after purchasing an additional 59,218 shares in the last quarter. 99.21% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms recently weighed in on VERA. HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of Vera Therapeutics in a research report on Wednesday, December 27th. Raymond James raised shares of Vera Therapeutics from an “outperform” rating to a “strong-buy” rating and increased their price objective for the stock from $29.00 to $37.00 in a research report on Friday, January 26th. Wedbush increased their target price on shares of Vera Therapeutics from $21.00 to $34.00 and gave the stock a “neutral” rating in a report on Thursday, March 21st. Oppenheimer began coverage on shares of Vera Therapeutics in a report on Thursday, January 25th. They set an “outperform” rating and a $26.00 target price on the stock. Finally, Cantor Fitzgerald began coverage on shares of Vera Therapeutics in a report on Monday, January 8th. They set an “overweight” rating on the stock. One investment analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and an average price target of $32.29.

About Vera Therapeutics

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.